Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12102477 | 0.79 | GABRA1 (0.33) | MAPTGABRA1GABRB2 | |
| SCHEMBL861791 | 0.77 | MAPT (0.42) | MAPTKDM4EGAAALDH1A1TSHR | |
| SCHEMBL8061776 | 0.75 | CASP1 (0.43) | MAPTKDM4EGAAALDH1A1TSHR | |
| SCHEMBL12102411 | 0.73 | ACE2 (0.41) | MAPTKDM4EGAAALDH1A1MAPK1 | |
| SCHEMBL2662565 | 0.73 | GABRA1 (0.47) | TSHRGABRA1GABRB2 | |
| SCHEMBL30644807 | 0.73 | ALDH1A1 (0.48) | MAPTKDM4EGAAALDH1A1TSHR | |
| SCHEMBL12102392 | 0.73 | KDM4E (0.50) | MAPTKDM4EGAAALDH1A1 | |
| SCHEMBL10269455 | 0.72 | MAPT (0.39) | MAPTKDM4EGAAALDH1A1TSHR | |
| SCHEMBL20223445 | 0.72 | ADRA2B (0.44) | MAPTKDM4EGAAALDH1A1TSHR | |
| SCHEMBL1293112 | 0.71 | KDM4E (0.47) | MAPTKDM4EGAAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389508-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-20110269738-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269738-A1 | COMPOUNDS | CYP11B2, CYP11B1, GPR119 | MAPT 719/4885KDM4E 3985/4885GAA 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.